Co-existence of trichomoniasis and BV-related pathogens is common2
Bacterial vaginosis (BV) provides a high pH, creating a favorable environment for T. vaginalis.3
Vaginal pH

SOLOSEC effectively treats both BV and trichomoniasis with just one oral dose1.


Non-compliance to a multiple-day metronidazole regimen is a contributing factor to persistent trichomoniasis or BV4,5
As many as 50%
of patients are non-compliant with a 7-day BID metronidazole regimen.6
SOLOSEC provides complete treatment for trichomoniasis and/or BV with a single oral dose.1
Untreated or inadequately treated trichomoniasis is associated with serious health risks and reproductive morbidity5,7:
Pelvic inflammatory disease (PID)8
Acquisition of STIs ((gonorrhea, chlamydia, HPV and HSV)9
Acquisition or transmission of HIV9
Cervical cancer10
Pregnancy
complications 11,12
(pre-term birth, low birth weight, premature rupture of membranes, chorioamnionitis)
Pelvic inflammatory disease (PID)8
Acquisition of STIs ((gonorrhea, chlamydia, HPV and HSV)9
Acquisition or transmission of HIV9
Cervical cancer10
Pregnancy complications 11,12
(pre-term birth, low birth weight, premature rupture of membranes, chorioamnionitis)

CDC recommends screening for trichomoniasis in all women seeking care for vaginal discharge.7

Trichomoniasis is highly recurrent, likely due to reinfection by infected partners7
Trichomoniasis Recurrence13


Left untreated, trichomoniasis can persist for months—or years.



With SOLOSEC, patients and partners can complete treatment for trichomoniasis with a single, effective 2 g oral dose



SOLOSEC delivers potent antimicrobial dosing in a single 2 g oral dose.1
A single 2 g oral dose achieves maximum plasma concentration 4 hours after dosing, with fast systemic absorption.1


* Assumes complete adherence to 500 mg BID metronidazole regimen. This is a pictorial representation of 2 products' pharmacokinetic profiles. There is no peer-reviewed study directly comparing the pharmacokinetics of SOLOSEC and metronidazole.
Comparative Half-Lives of 5-Nitroimidazole Compounds14,15


The long half-life of secnidazole supports a 1-day, single dose regimen of SOLOSEC.14
The long half-life of secnidazole supports a 1-day, single dose regimen of SOLOSEC.14



SOLOSEC offers an effective solution to assure adherence in patients and partners without the need for multiple days of pills.1

SOLOSEC 2 g ONCE


1 dose
Metronidazole 500 mg
BID x 7 days*


14 doses
*CDC recommended oral regimen for both BV and trichomoniasis
References:
1. SOLOSEC [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals, Inc; 2021. 2. Sobel JD, Subramanian C, Foxman B, Fairfax M, Gygax S. Mixed Vaginitis—More than Coinfection and with Therapeutic Implications. Curr Infect Dis Rep 2013;15:104-108. 3. Brotman RM. Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective. J Clin Invest. 2011;121(12):4610-4617. 4. Marrazzo JM, Thomas KK, Fledler TL, Ringwood K, Fredricks DN. Relationship of Specific Vaginal Bacteria and Bacterial Vaginosis Treatment Failure in Women Who Have Sex with Women. Ann Intern Med 2008;149:20-28. 5. Kissinger P. Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. BMC Infect Dis 2015;15(307);1-8. 6. Bartley JB, Ferris DG, Allmond LM, Dickman ED, Dias JK, Lambert J. Personal digital assistants used to document compliance of bacterial vaginosis treatment. Sex Transm Dis 2004;31(8):488-491.23. 7. Workowski KA, Bachmann LH, Chan PA, et al. CDC Sexually Transmitted Diseases Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(RR-04):1-192 8. Wiringa AE, Ness RB, Darville T et al. Trichomonas vaginalis, endometritis and sequelae among women with clinically suspected pelvic inflammatory disease. Sex Transm Infect 2020;96:436-438. 9. Allsworth JE, Ratner JA, Peipert JF. Trichomoniasis and other sexually transmitted infections: results from the 2001–2004 National Health and Nutrition Examination Surveys. Sex Transm Infect 2009;36(12):738–44. 10. Yang S, Zhao W, Wang H, et al. Trichomonas vaginalis infection-associated risk of cervical cancer: A meta-analysis. Euro J Obstet Gynecol 2018;228:166-173. 11. Van Gerwen OT, Craig-Kuhn MC, Jones AT et al. Trichomoniasis and adverse birth outcomes: a systematic review and meta-analysis. BJOG 2021. 12. Cotch MF, Pastorek JG 2nd, Nugent RP, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. Sex Transm Dis 1997;24:353-360 and 563-568. 13. Peterman TA, Tian LH, Metcalf CA, et al. High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: a case for rescreening. Ann Intern Med2006;145:564–72. 14. Nyirjesy P, Schwebke JR. Secnidazole: Next-generation antimicrobial agent for bacterial vaginosis treatment. Future Microbiol 2018;13:507-524. 15. Gillis JC, Wiseman LR. Secnidazole. A Review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs1996;51(4):621-638.